Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Safra, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Safra, T.
The Oncologist, Vol. 8, Suppl 2, 17–24, August 2003
© 2003 AlphaMed Press

Cardiac Safety of Liposomal Anthracyclines

Tamar Safra

Institute of Oncology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

Correspondence: Tamar Safra, M.D., Institute of Oncology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel 64239. Telephone: 972-3-6974831; Fax: 972-3-6974828; e-mail: safrat{at}bezeqint.net

Anthracyclines have demonstrated antitumor activity in a variety of cancers; however, irreversible cardiac damage is a major dose-limiting toxicity, restricting lifetime cumulative dose. The most successful strategy to improve the cardiac safety of anthracyclines to date involves liposomal encapsulation, which alters the tissue distribution and pharmacokinetics of these agents. The cardiac safeties of liposomal daunorubicin, liposomal doxorubicin (D-99), and pegylated liposomal doxorubicin have been studied in several clinical trials. The lack of published data comparing liposomal daunorubicin with conventional daunorubicin makes it difficult to draw meaningful conclusions regarding the relative cardiac safeties of these formulations. Studies indicate that the risk of anthracycline-induced cardiotoxicity is considerably lower with liposomal doxorubicin formulations than with conventional doxorubicin. Pegylated liposomal doxorubicin has been studied most extensively and has demonstrated the most significant reductions in risk for cardiotoxicity. Compared with conventional doxorubicin, pegylated liposomal doxorubicin has shown similar efficacy with a significantly lower incidence of cardiotoxicity and significantly fewer cardiac events. Although the long-term cardiac safety of these agents is unknown, data suggest that liposomal anthracyclines, particularly pegylated liposomal doxorubicin, may offer a significant clinical benefit for patients with higher risks for anthracycline-induced cardiotoxicity.

Key Words. Anthracyclines • Liposome • Doxorubicin • Drug toxicity • Breast neoplasms




This article has been cited by other articles:


Home page
Ann OncolHome page
E Andreopoulou, D Gaiotti, E Kim, A Downey, D Mirchandani, A Hamilton, A. Jacobs, J. Curtin, and F Muggia
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil(R)): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer
Ann. Onc., April 1, 2007; 18(4): 716 - 721.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
J-H Chen, R Ling, Q Yao, Y Li, T Chen, Z Wang, and K-Z Li
Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model
Endocr. Relat. Cancer, March 1, 2005; 12(1): 93 - 100.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. O'Shaughnessy
Liposomal Anthracyclines for Breast Cancer: Overview
Oncologist, August 1, 2003; 8(90002): 1 - 2.
[Full Text] [PDF]


Home page
The OncologistHome page
E. Rivera
Liposomal Anthracyclines in Metastatic Breast Cancer: Clinical Update
Oncologist, August 1, 2003; 8(90002): 3 - 9.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. Campos
Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer
Oncologist, August 1, 2003; 8(90002): 10 - 16.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. C. Wolff
Liposomal Anthracyclines and New Treatment Approaches for Breast Cancer
Oncologist, August 1, 2003; 8(90002): 25 - 30.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2003 by AlphaMed Press.
Advertisement